← Back to Search

Mesh Implant

DuraSorb® Mesh for Breast Reconstruction

N/A
Waitlist Available
Research Sponsored by Surgical Innovation Associates, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 month follow-up
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a special surgical mesh called DuraSorb® in women having breast reconstruction after mastectomy. The mesh helps support the new breast shape as it heals. The study will compare results with past surgeries that did not use any mesh. DuraSorb is designed for soft tissue reinforcement, known for its ease of handling and rapid tissue incorporation.

Who is the study for?
This trial is for women aged 22-70 planning to have breast reconstruction with a mesh after mastectomy. They must be able to attend all visits, understand the study, and consent. Exclusions include prior failed reconstructions or radiation at the site, extreme BMI values, certain medications, recent nicotine use, pregnancy plans during the study, and any health issues that increase surgery risks.
What is being tested?
The trial is testing DuraSorb®, a type of surgical mesh used in breast reconstruction post-mastectomy. It compares outcomes like safety and effectiveness between patients receiving this new mesh versus those who had similar surgeries without it.
What are the potential side effects?
While specific side effects are not listed here, surgical meshes can typically cause complications such as infection at the surgery site, pain or discomfort around the area where they're implanted, possible allergic reactions or rejection by body tissue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 month follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Composite Clinical Success (CCS)
Local Complications of Breast Reconstruction

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment ArmExperimental Treatment1 Intervention
Group II: Historical Control ArmActive Control1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Mesh-based breast reconstruction treatments work by providing structural support to the reconstructed breast using synthetic or biological mesh materials. These meshes act as scaffolds that reinforce the tissue and support the implant or tissue flap, promoting tissue integration and stability. This mechanism is crucial for achieving a natural breast shape and reducing complications such as implant displacement or capsular contracture. For patients, understanding these benefits is important as it can lead to better aesthetic outcomes and fewer postoperative issues.

Find a Location

Who is running the clinical trial?

Surgical Innovation Associates, Inc.Lead Sponsor

Media Library

DuraSorb® (Mesh Implant) Clinical Trial Eligibility Overview. Trial Name: NCT04646057 — N/A
Breast Reconstruction Research Study Groups: Treatment Arm, Historical Control Arm
Breast Reconstruction Clinical Trial 2023: DuraSorb® Highlights & Side Effects. Trial Name: NCT04646057 — N/A
DuraSorb® (Mesh Implant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04646057 — N/A
~34 spots leftby Dec 2025